Clinical trials: Blood Cell Count
HIV Infections
Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy
The purpose of this study is to see if it is safe and effective to give HIV-positive patients L2-7001 (a type of interleukin-2) plus anti-HIV therapy.
- Trial name
- NCT00002449
- Testing
- Aldesleukin
- Where
- 23 sites in United States
- Volunteers
- 212 people
- Sponsor
- Chiron Corporation
Cytomegalovirus Infections, HIV Infections
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
To evaluate the safety and efficacy of adefovir dipivoxil in prolonging survival of patients with advanced HIV disease. In CMV prophylaxis substudy: To evaluate the efficacy of adefovir dipivoxil in preventing the development of…
- Trial name
- NCT00001082
- Testing
- Levocarnitine, Adefovir dipivoxil
- Where
- 15 sites in United States
- Volunteers
- 505 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy.
- Trial name
- ESPRIT (NCT00004978)
- Testing
- Recombinant interleukin-2 (rIL-2)
- Where
- 248 sites in United States, Argentina and 23 more
- Volunteers
- 4,150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Preterm Birth, Umbilical Cord Clamping
Umbilical Cord Clamping Methods and Stem Cell Counts in Preterm Infants
This study evaluates the effect of different umbilical cord clamping methods on peripheral blood hematopoietic stem cell counts in preterm newborns.
- Trial name
- NCT07385326
- Testing
- Immediate Cord Clamping, Delayed Cord Clamping, Umbilical Cord Milking
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Era Tufan Benli
HIV Infections
The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
To compare the durability of the viral load response following 48 weeks of treatment with 1592U89/lamivudine (3TC)/zidovudine (ZDV) versus 3TC/ZDV alone.
- Trial name
- NCT00002389
- Testing
- Abacavir sulfate, Lamivudine, Zidovudine
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 210 people
- Sponsor
- Glaxo Wellcome
HIV
A Pilot Study to Examine Efficacy of Peer Mentoring in Promoting Medication Adherence Among People Living With HIV/AIDS
This study aims to investigate the effectiveness of an in-person peer mentoring and health literacy intervention on improving medication adherence, HIV-1 viral load, CD4+ T lymphocyte counts, and HIV medical appointment…
- Trial name
- NCT02025322
- Testing
- Peer Mentoring
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Jury Candelario
Chronic Obstructive Pulmonary Disease
Regulatory T Cells in COPD
Lymphoid follicles, consisting of T-and B cells, are involved in the chronic inflammatory response in COPD. Foxp3 positive regulatory T cells (Tregs) are present in these follicles and may be involved in the suppression of this…
- Trial name
- NCT00452764
- Testing
- Withdrawal of medication
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Groningen Research Institute for Asthma and COPD
Red-Cell Aplasia, Pure
A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins
The purpose of this study is to record the number of participants with chronic renal disease who are receiving treatment with epoetin alfa or other recombinant erythropoietins who develop pure red cell aplasia (PRCA, a rare form…
- Trial name
- NCT00211029
- Volunteers
- 4,670 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Neutropenia (Low White Blood Cell Count)
A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)
This is a study comparing two study drugs, Filgrastim Hospira and Neupogen®. Neupogen® is approved by the US Food and Drug Administration (FDA) to treat low numbers of specific kinds of white blood cells (WBC) known as…
- Trial name
- NCT02766647
- Testing
- Filgrastim Hospira (US), US-approved Neupogen®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy, Blood Cell Count
Blood Testing at Entia
The investigators are recruiting healthy volunteers to donate 1-5 (depending on study visits. and donors will be notified upon invitation) finger prick blood samples or venous samples to Entia for the further development and…
- Trial name
- NCT05580055
- Testing
- Affinity
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Entia Ltd
Multiple Myeloma, Lymphoma, Non-Hodgkin
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with…
- Trial name
- NCT00396266
- Testing
- G-CSF Plus Plerixafor
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Genzyme, a Sanofi Company
Myelogenous Leukemia, Chronic
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, were compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+)…
- Trial name
- ENESTnd (NCT00471497)
- Testing
- nilotinib, imatinib
- Where
- 213 sites in United States, Argentina and 33 more
- Volunteers
- 846 people
- Sponsor
- Novartis Pharmaceuticals
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Immune Markers, Complete Blood Count (CBC) With Platelet Differentials
Immune and Recovery Modulating Impact of Probiotic Supplementation After Intense Resistance Exercise
This study proposal seeks to examine the efficacy of probiotic supplementation at mitigating changes in immune function and recovery after completion of intense, stressful exercise while also allowing for a better understanding…
- Conditions
- Immune Markers, Complete Blood Count (CBC) With Platelet Differentials, Muscle Damage, Muscular Force Production
- Trial name
- NCT04441840
- Testing
- Active Probiotic Culture, Inactive Probiotic Culture
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Lindenwood University
Abdominal Aortic Aneurysm, Coronary Artery Disease
White Blood Cell Counts and Onset of Cardiovascular Diseases: a CALIBER Study
The complete blood count is a commonly performed blood test, and previous small studies have suggested that the counts of some types of white blood cell in the complete blood count may be related to the onset of cardiovascular…
- Conditions
- Abdominal Aortic Aneurysm, Coronary Artery Disease, Stroke, Heart Failure
- Trial name
- CALIBER (NCT02014610)
- Volunteers
- 800,000 people, healthy volunteers welcome
- Sponsor
- University College, London
Periodontitis, Gingivitis
Relationship Between Periodontal Inflammation Severity and Pan-Immune System Inflammation Value
This cross-sectional observational study aims to evaluate the relationship between periodontal inflammation severity and the Pan-Immune-Inflammation Value (PIV) in systemically healthy adults.
- Conditions
- Periodontitis, Gingivitis, Periodontal Health
- Trial name
- NCT07628803
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Abant Izzet Baysal University
Modic Changes
Complete Blood Count-derived Indexes in Inflammatory Modic Changes
Some indicators generated from hemogram such as neutrophil/lymphocyte (NLR) have been suggested as biomarkers of systemic inflammation.
- Trial name
- NCT06440096
- Testing
- hemogram
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- Veysel Delen, MD
Coronary Heart Disease
Association Between Mitochondrial DNA Content and Risk of Coronary Heart Disease
Compelling epidemiological evidence indicates that alterations of mitochondrial DNA, including mutations and abnormal content of mitochondrial DNA (mtDNA), are associated with the initiation and development of cardiovascular…
- Trial name
- NCT02500823
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Air Force Military Medical University, China
Pregnancy Related
Reference Intervals of Complete Blood Count and Coagulation Tests in Pregnant Women at Hung Vuong Hospital
Rationale: Pregnancy has major effects on physiology in women. There have been many studies that established reference intervals but none was done in Vietnam.
- Trial name
- NCT05929326
- Testing
- complete blood count, PT, aPTT, fibrinogen tests
- Where
- Vietnam
- Volunteers
- 879 people, healthy volunteers welcome
- Sponsor
- Hung Vuong Hospital
Multiple Myeloma
Finistere Myeloma Observatory (OMYFIN)
Current molecular risk stratification of multiple myeloma (MM), based on the presence of t(4 ;14) and 17p deletion, cannot fully explain treatment outcome heterogeneity, as other features also predict prognosis.
- Trial name
- OMYFIN (NCT06552221)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest